Patents Assigned to The Board of Trustees of the University of Arkansas System
  • Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
    Patent number: 7659062
    Abstract: Oligonucleotide microarrays were used to profile and compare gene expression patterns between uterine serous papillary carcinoma and ovarian serous papillary carcinoma or normal endometrial epithelial cells. mRNA fingerprints readily distinguish the more biologically aggressive and chemotherapy resistant USPC from OSPC or NEC. Plasminogen activator inhibitor is the most highly up-regulated gene in OSPC relative to USPC, whereas the c-erbB2 gene product (HER-2/neu) is strikingly overexpressed in USPC relative to OSPC and may therefore represent a novel diagnostic and therapeutic marker for this highly aggressive subset of endometrial tumors.
    Type: Grant
    Filed: June 1, 2004
    Date of Patent: February 9, 2010
    Assignee: The Board of Trustee of the University of Arkansas System
    Inventor: Alessandro D. Santin
  • Maternal multi-nutrient against diabetes-related birth defects
    Patent number: 7438933
    Abstract: The present invention provides uses of multi-nutrient supplements to rescue aberrant biochemical pathways and reduce birth defect caused by maternal diabetes. Choice of supplements is based on the ability of each supplement to correct the following hyperglycemia-associated abnormalities: increased reactive oxygen species generation, abnormal membrane phospholipid metabolism, and decreased glutathione synthesis.
    Type: Grant
    Filed: December 9, 2005
    Date of Patent: October 21, 2008
    Assignee: The Board of Trustees of the University of Arkansas System
    Inventors: YingKing Wu, E. Albert Reece
  • Transmembrane serine protease overexpressed in ovarian carcinoma and uses thereof
    Patent number: 7265216
    Abstract: The present invention provides a transmembrane serine protease TADG-12 protein, splice variants of the TADG-12 protein and DNA fragments encoding such proteins. Also provided are vectors and host cells capable of expressing the DNAs. The present invention further provides various methods of early detection and therapies of associated ovarian and other malignancies by utilizing the DNAs and/or proteins disclosed herein.
    Type: Grant
    Filed: February 3, 2003
    Date of Patent: September 4, 2007
    Assignee: The Board of Trustees of the University of Arkansas System
    Inventor: Timothy J. O'Brien
  • Extracellular serine protease
    Patent number: 7157084
    Abstract: The present invention provides a DNA encoding a novel extracellular serine protease termed Tumor Antigen Derived Gene-14 (TADG-14) which is overexpressed in ovarian, breast and colon carcinoma samples. Also provided are vector and host cells capable of expressing the DNA of the present invention, as well as the uses of the DNA and protein of the present invention.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: January 2, 2007
    Assignee: The Board of Trustees of The University of Arkansas System
    Inventors: Timothy J. O'Brien, Lowell J. Underwood
  • Extracellular serine protease
    Patent number: 7083790
    Abstract: The present invention provides a DNA encoding a novel extracellular serine protease termed Tumor Antigen Derived Gene-14 (TADG-14) which is overexpressed in ovarian, breast and colon carcinoma samples. Also provided are vector and host cells capable of expressing the DNA of the present invention, as well as the uses of the DNA and protein of the present invention.
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: August 1, 2006
    Assignee: The Board of Trustees of the University of Arkansas Systems
    Inventors: Timothy J. O'Brien, Lowell J. Underwood
  • Transmembrane serine protease overexpressed in ovarian carcinoma and uses thereof
    Patent number: 7067630
    Abstract: The present invention provides a TADG-12 protein and a DNA fragment encoding such protein. Also provided is a vector/host cell capable of expressing the DNA. The present invention further provides various methods of early detection of associated ovarian and other malignancies, and of interactive therapies for cancer treatment by utilizing the DNA and/or protein disclosed herein.
    Type: Grant
    Filed: June 5, 2003
    Date of Patent: June 27, 2006
    Assignee: The Board of Trustees of The University of Arkansas System
    Inventors: Timothy J. O'Brien, Lowell J. Underwood
  • Human cytoplasmic polyadenylation element binding protein and uses thereof
    Patent number: 7030224
    Abstract: The present invention provides genomic and cDNA encoding human cytoplasmic polyadenylation element binding protein, expression vectors comprising human cytoplasmic polyadenylation element binding protein cDNA and host cells that contain the expression vectors. Also provided are recombinant human cytoplasmic polyadenylation element binding protein and polypeptides derived thereof.
    Type: Grant
    Filed: January 23, 2003
    Date of Patent: April 18, 2006
    Assignee: The Board of Trustees of the University of Arkansas System
    Inventor: Angus M. MacNicol
  • Methods for the early diagnosis of ovarian and prostate cancer
    Patent number: 6518028
    Abstract: The disclosed nucleic acid primer sets, used in combination with quantitative amplification (PCR) of tissue cDNA, can indicate the presence of specific proteases in a tissue sample. The detected proteases are themselves specifically overexpressed in certain cancers, and the presence of their genetic precursors may serve for early detection of associated ovarian and other malignancies, and for the design of interactive therapies for cancer treatment.
    Type: Grant
    Filed: May 21, 2001
    Date of Patent: February 11, 2003
    Assignee: The Board of Trustees of the University of Arkansas System
    Inventor: Timothy L. O'Brien